Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects

Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Mosc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human vaccines & immunotherapeutics Jg. 18; H. 5; S. 2060018
Hauptverfasser: Borgonovo, Fabio, Stangalini, Carlo Alberto, Tinelli, Carmine, Mariani, Chiara, Mileto, Davide, Cossu, Maria Vittoria, Abbati, Laura, Bilardo, Lara, Gagliardi, Gloria, Cutrera, Miriam, Pellicciotta, Martina, Armiento, Luciana, Dedivitiis, Gianfranco, Capetti, Amedeo F., Rizzardini, Giuliano
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Taylor & Francis 30.11.2022
Taylor & Francis Group
Schlagworte:
Aged
Antibodies, Viral
antibody
BNT162 Vaccine
Brief Report
Coronavirus – Short Report
covid-19
COVID-19 - prevention & control
decline
Humans
igg
Immunoglobulin G
kinetics
SARS-CoV-2
spike
Vaccination
vaccine
COVID-19
SARS-CoV-2
vaccine
antibody
IgG
decline
kinetics
spike
ISSN:2164-5515, 2164-554X, 2164-554X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Moscati" who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.1080/21645515.2022.2060018